Puma Biotechnology Inc news

   Watch this stock
Showing stories 1 - 10 of about 93   

Articles published

PBYI 67.05 0.00 (0.00%)
price chart
Eagle Asset Management Inc. Takes Position in Puma Biotechnology Inc (PBYI)
Eagle Asset Management Inc. acquired a new position in shares of Puma Biotechnology Inc (NASDAQ:PBYI) during the fourth quarter, HoldingsChannel reports.
Here's Why Puma Biotechnology Inc. Is Getting Beaten Down Today
What happened. Shares of Puma Biotechnology Inc. (NASDAQ:PBYI), a U.S. biotech seeking approval of its breast cancer therapy in the EU, were hit hard after European regulators signaled big trouble for the company's lead drug.
Puma Biotechnology sinks after Europe unlikely to OK breast cancer drug  Reuters
Puma Plunges as Cancer Drug Setback Stuns Wall Street  Bloomberg
Puma Biotechnology: EU Delivers A Blow - And An Opportunity
Puma Biotechnology (PBYI) took a nasty hit on January 23rd, when the EMA, the EU's equivalent of the FDA, through up a serious roadblock to the approval of the company's drug Nerlynx - also called neratinib - for the treatment of early-stage HER2 ...
Ascend Capital LLC Position In Puma Biotechnology INC (PBYI) Was Has Lifted
Investors sentiment increased to 1.55 in Q3 2017. Its up 0.34, from 1.21 in 2017Q2. It increased, as 19 investors sold PBYI shares while 41 reduced holdings.
Ascend Capital LLC Has Upped Its Puma Biotechnology INC (PBYI) Holding by ...  Frisco Fastball
38550 Shares in Puma Biotechnology Inc (PBYI) Purchased by Dimensional Fund ...  StockNewsTimes
Puma Biotechnology to Present at LEERINK Partners Global Healthcare Conference
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 3:30 p.m ...
Puma Biotechnology Inc (NASDAQ:PBYI): Risks You Need To Consider Before Buying
If you are looking to invest in Puma Biotechnology Inc's (NASDAQ:PBYI), or currently own the stock, then you need to understand its beta in order to understand how it can affect the risk of your portfolio.
Dimensional Fund Advisors LP Invests $4.62 Million in Puma Biotechnology Inc ...  StockNewsTimes
Why Investors remained confident on Puma Biotechnology, Inc. (PBYI ...
ROI deals with the invested cash in the company and the return the investor realize on that money based on the net profit of the business.
$-2.04 EPS Expected for Puma Biotechnology, Inc. (PBYI)  BZ Weekly
Puma Biotechnology Inc (PBYI) Soars 10.95% on February 14
Puma Biotechnology Inc (PBYI) had a good day on the market for Wednesday February 14 as shares jumped 10.95% to close at $68.40.
Puma Biotechnology Inc (PBYI) Plunges 5.05% on February 05
Puma Biotechnology Inc (PBYI) had a rough trading day for Monday February 05 as shares tumbled 5.05%, or a loss of $-3.25 per share, to close at $61.10.
Puma Biotechnology (PBYI) Getting Somewhat Favorable News Coverage, Report Finds  Week Herald
Redmile Group Lifted Puma Biotechnology (PBYI) Position; As Csx (CSX) Share ...  Thorold News
Puma Biotechnology, Inc. (PBYI) registers a price change of -1.54% while Jazz ...
In latest trading activity; Puma Biotechnology, Inc. (PBYI) snatched the consideration from Investors, when its current damaging picture was seen that is promoting bad performance.